Critically important containment measures have been shown to ‘flatten the curve’ of new SARS-CoV-2 infections, save lives and ease the pressure on healthcare systems and medical supplies. At the same time, there are indications that these and other COVID-19 related measures will, depending on their extent and duration, also impact on the future mortality and morbidity trends of other areas of disease and health.
Munich Re assessed the effectiveness of Milliman Irix® Risk Score 2.2 in stratifying the mortality for the U.S. insurance applicant population.
Predictive models are an incredibly powerful tool with the potential to drive the life insurance industry forward in ways that are good for both consumers (improving their purchasing experience by removing intrusive requirements and long delays) and carriers (increasing taken rates and persistency, and increasing the accuracy of mortality assessments).
The incidence of melanoma is rising in much of the world, and it is now the fifth most commonly diagnosed cancer in North America.
Why do some COVID-19 patients experience critically low blood-oxygen readings? Why has mechanical ventilation been of varying benefit? RGA's Heather Lund explores these and other pertinent questions surrounding COVID-19-associated coagulation abnormalities. Insights shared and learned can only help to better understand, manage, and predict possible disease outcomes of this novel pathogen.
Tele-interviews, when carried out by well trained individuals, ideally with a medical, nursing or underwriting background, can bring new and more detailed disclosures than may be the case when applicant is questioned by an agent or broker.
Nonalcoholic steatohepatitis (NASH) is a more aggressive form of liver disease. It is inflammatory in nature, is much quicker in disease progression than the standard type and may result in liver cirrhosis and failure. Both in clinical practice and in underwriting, NASH is under-recognized in its incidence. It actually affects up to five percent of the United States population and its prevalence is on the rise.
There remains much debate about Coronavirus and the many ways in which it has affected, is affecting and will affect societies: for example, the death tolls so far and in future, ways to suppress its activity, the value of testing, tracing and monitoring, the economic impact of ‘lockdowns’ and whether governments have responded appropriately in a timely manner.
How can medical advancements extend a healthy lifespan and combat the diseases of old age?
Life insurers need actionable responses to current underwriting challenges – including the need for fluidless Accelerated Underwriting alternatives, while striving to maintain the same level of mortality.